Time to event end points and response rates were similar regardless of which first-line immunotherapy was administered, according to an analysis conducted by the International Metastatic Renal Cell Carcinoma Database Consortium
Time to event end points and response rates were observed in patients with advanced renal cell carcinoma who received cabozantinib (Cabometyx, Cometriq) in the second-line setting after being treated with immune-oncology combinations in the frontline, according to a data set from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) presented during the 2022 ASCO Genitourinary Cancers Symposium. In addition, investigators evaluated outcomes for patients who received approved third-line treatment after second-line cabozantinib.
Broadly, the median time to treatment failure (TTF) was 7.59 months (95% CI, 6.61-8.98), median overall survival (OS) was 18.12 months (95% CI, 15.42-24.10), the 1-year treatment failure free rate was 34.3%, the 1-year OS was 63.5%, and the overall response rate (ORR) was 26.2%, according to lead author Vishal Navani, MA, MBBS, a medical oncology fellow at the University of Calgary, Tom Baker Cancer Centre, Alberta, Canada.
Limited data are available about the activity of cabozantinib in the second line after first-line standard of care immunotherapy: ipilimumab (Yervoy) plus nivolumab (Opdivo) or immune-oncology/vascular endothelial growth factor (VEGF) inhibitor combinations (IOVE).
A total of 364 patients were identified who had received cabozantinib in the second line. In the first-line setting, 78 patients had received the ipilimumab plus nivolumab combination, 46 patients received the IOVE combination, and 222 patients received other first-line treatment. ORR, TTF, and OS were key end points. Hazard ratios (HRs) were adjusted for favorable, intermediate, and poor risk groups.
When outcomes for second-line cabozantinib were stratified by frontline therapy, investigators reported that patients who received ipilimumab plus nivolumab had a median TTF of 6.90 (95% CI, 6.05-not evaluable [NE]), a median OS of 21.44 months (95% CI, 12.07-NE), 1-year treatment failure free rate of 34.3%, 1-year OS of 66.6%, and an ORR of 26.4% (14/53 patients).
In patients treated with front-line IOVE, the median TTF was 5.72 months (95% CI, 4.41-NE), median OS was 15.68 months (95% CI, 9.27-NE), 1-year treatment failure free rate of 26.8%, the 1-year OS was 54.3%, and the ORR was 32.5% (13/40 patients).
In patients treated with a first-line therapy other than immunotherapy, the median TTF was 7.96 months (95% CI, 6.81-9.63), median OS was 18.41 months (95% CI, 14.99-25.78), 1-year treatment failure free rate of 35.7%, 1-year OS was 63.5%, and the ORR was 23.9% (43/180 patients).
After adjusting for IMDC risk groups, investigators reported that the HRs for second-line cabozantinib OS and TTF for IOVE vs ipilimumab plus nivolumab were 1.73 (95% CI, 0.83-3.62; P = .14) and 1.62 (95% CI, 0.89-2.95; P = .11), respectively.
When patients who received third-line therapy (n = 125) were stratified by second-line cabozantinib, investigators found that the median TTF was 3.22 months (95% CI, 2.76-5.82), the median OS was 10.92 months (95% CI, 9.44-20.02), the 1-year treatment failure free rate was 19.9%, the 1-year OS was 48.4%, and the ORR was 13.3% (12/90 patients).
The investigators concluded that time to event end points and response rates were similar regardless of which first-line immunotherapy was administered. In the third-line setting, post cabozantinib treatment, single-agent VEGF inhibitors also have activity, but as expected, response was diminished compared with earlier lines of therapy, wrote the investigators.
REFERENCE
Navani V, Wells C, Boyne DJ, et al. CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). J Clin Oncol. 2022;40suppl 6; abstr 318). doi: 10.1200/JCO.2022.40.6_suppl.318
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
DREAMM-8 Trial Demonstrates Benefits of Belantamab Mafodotin
October 3rd 2024Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.
Read More